JGNYC
Posted - 2 weeks ago
$CSLLY when they dropping the new bird flu vaccine?
Jeko44
Posted - 1 month ago
$CSLLY still
Jeko44
Posted - 1 month ago
$CSLLY
Financhill
Posted - 3 months ago
$CSLLY is rated a Sell since January 16, 2024 and is 28% below its median level.
Stock_Titan
Posted - 3 months ago
$CSLLY CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
DonCorleone77
Posted - 4 months ago
$ARCT $CSLLY Arcturus Therapeutics and CSL' ARCT-154 shows superior immunogenicity Arcturus Therapeutics and CSL announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty. ARCT-154 results were achieved with one-sixth the dose of Comirnaty. Both vaccines were well-tolerated, with no causally associated severe or serious adverse events. The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan. The phase 3 study results with ARCT-154 were used to support the approval of ARCT-154 for primary immunization and as a booster dose in Japan in November of this year....
DonCorleone77
Posted - 4 months ago
$ARCT $CSLLY Arcturus Therapeutics, CSL publish data on booster dose of ARCT-154 CSL and Arcturus Therapeutics announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA, or sa-mRNA, vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty. ARCT-154 results were achieved with one sixth the dose of Comirnaty. The study included healthy adults initially immunized with two doses of an mRNA vaccine; and then a third dose of Comirnaty at least three months prior to the booster dose of either ARCT-154 or Comirnaty in the study. Both vaccines were well-tolerated, with no causally associated severe or serious adverse events. The study was conducted in partnership with Meiji Seika Pharma...
Stock_Titan
Posted - 4 months ago
$CSLLY $ARCT CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Stock_Titan
Posted - 4 months ago
$ARCT $CSLLY CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
DonCorleone77
Posted - 11/28/23
$CSLLY $ARCT CSL's and Arcturus Therapeutics' mRNA vaccine for COVID approved in Japan CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that Japan's Ministry of Health, Labor and Welfare granted approval for ARCT-154, a self-amplifying mRNA COVID-19 vaccine for initial vaccination and booster for adults 18 years and older. The approval is based on positive clinical data from several ARCT-154 studies. CSL's vaccine business, CSL Seqirus, one of the largest influenza vaccine providers in the world, partnered exclusively with Meiji Seika Pharma for distribution of the sa-mRNA COVID vaccine, ARCT 154, in Japan.
Stock_Titan
Posted - 11/28/23
$CSLLY $ARCT Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Article Available on StockTitan Website.
Stock_Titan
Posted - 11/28/23
$ARCT $CSLLY Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
Article Available on StockTitan Website.
STCKPRO
Posted - 5 months ago
$CSLLY NEW ARTICLE : Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment https://www.stck.pro/news/CSLLY/68343270/
Stock_Titan
Posted - 5 months ago
$CSLLY Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
Article Available on StockTitan Website.
Stock_Titan
Posted - 6 months ago
$CSLLY $QURE CSL and uniQure Win 2023 Prix Galien USA Award
https://www.stocktitan.net/news/CSLLY/csl-and-uni-qure-win-2023-prix-galien-usa-eqzrabdx3fs4.html
Stock_Titan
Posted - 6 months ago
$CSLLY New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
https://www.stocktitan.net/news/CSLLY/new-data-presented-at-id-week-2023-demonstrates-public-health-fj3vsti3hq8h.html
#vaccine
YaRangus
Posted - 09/28/23
$CSLLY Funny, no news about the plant on strike in the U.S. the one that provides the magi dirt of the plasma for the whole global company
dividendinvestorbyeagle
Posted - 7 months ago
$CSLLY hit 52 week low (ADR (Sponsored)/CSL Ltd) https://www.dividendinvestor.com/dividend-news/?symbol=cslly http://dlvr.it/SwV81W
dividendinvestorbyeagle
Posted - 7 months ago
$CSLLY hit 52 week low (ADR (Sponsored)/CSL Ltd) https://www.dividendinvestor.com/dividend-news/?symbol=cslly http://dlvr.it/SwV7Jy
Stock_Titan
Posted - 7 months ago
$CSLLY CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
https://www.stocktitan.net/news/CSLLY/csl-seqirus-presents-real-world-evidence-at-eswi-demonstrating-the-mrad05jjj715.html
STCKPRO
Posted - 7 months ago
$CSLLY NEW ARTICLE : CSL: Watch Out For Positive Surprises https://www.stck.pro/news/CSLLY/60723775/
STCKPRO
Posted - 08/28/23
$CSLLY NEW ARTICLE : CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine https://www.stck.pro/news/CSLLY/60064198/
Stock_Titan
Posted - 08/28/23
$CSLLY CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
https://www.stocktitan.net/news/CSLLY/csl-seqirus-announces-third-u-s-government-award-in-relation-to-i7l2ca4zueda.html
#vaccine
Stock_Titan
Posted - 08/28/23
$CSLLY Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
https://www.stocktitan.net/news/CSLLY/ferinject-r-granted-upgraded-recommendations-in-2023-esc-heart-atw14exzioho.html
STCKPRO
Posted - 8 months ago
$CSLLY NEW ARTICLE : CSL Appoints Jeffrey Ball as First Chief Sustainability Officer https://www.stck.pro/news/CSLLY/59102102/
sundancehold
Posted - 8 months ago
@buythehornz127 @Thickhog81 @NCpilot172 @Hogtrader1 @Jeko44 @Elamenape2 @roomza I'm not quite sure how to interpret it. $CSLLY They have a new CEO, maybe just a different formula for their poster material. Butler probably would of filed an 8K if their agreement has changed but maybe not.
STCKPRO
Posted - 8 months ago
$CSLLY NEW ARTICLE : CSL Limited NPATA of $2.38B, revenue of $13.31B https://www.stck.pro/news/CSLLY/58943538/
